Sutro Biopharma reported Q3 2026 results highlighting progress in its cancer drug pipeline, including STRO-004 and STRO-006 entering clinical trials and STRO-227 advancing toward trials in early 2027. The company received a $10 million milestone from partner Astellas for a dual-payload ADC program. With $142.2 million in cash and equivalents, Sutro expects to fund operations into the first half of 2028. Upcoming clinical updates and expansion cohorts are planned for 2027, reflecting Sutro's focus on innovative antibody-drug conjugates to improve cancer treatment outcomes.
Sutro Biopharma's Q3 2026 results provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: out of 150 priced US health stocks, 23 rose and 124 fell. Notable movers include SANA at USD 2.02 with a -11.79% change and a typical hold time of 26 days, CTXR at USD 0.53 with +11.19% change and 19 days hold, and SMMT at USD 15.10 with -9.25% change and 19 days hold.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
